Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Federal Trade Commission
Argus Health
McKinsey
Deloitte
Fish and Richardson
Merck
Express Scripts
Cantor Fitzgerald

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020873

« Back to Dashboard

NDA 020873 describes ANGIOMAX, which is a drug marketed by The Medicines Co and is included in one NDA. It is available from two suppliers. There are two patents protecting this drug and one Paragraph IV challenge. Additional details are available on the ANGIOMAX profile page.

The generic ingredient in ANGIOMAX is bivalirudin. There are thirteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for 020873
Tradename:ANGIOMAX
Applicant:The Medicines Co
Ingredient:bivalirudin
Patents:2
Formulation / Manufacturing:see details
Pharmacology for NDA: 020873
Mechanism of ActionThrombin Inhibitors
Suppliers and Packaging for NDA: 020873
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873 NDA AUTHORIZED GENERIC Sandoz 0781-3158 N 0781-3158-95
ANGIOMAX bivalirudin INJECTABLE;INTRAVENOUS 020873 NDA AUTHORIZED GENERIC Sandoz 0781-9158 N 0781-9158-95

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INTRAVENOUSStrength250MG/VIAL
Approval Date:Dec 15, 2000TE:APRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jan 27, 2029Product Flag?Substance Flag?Delist Request?Y
Patent:➤ Sign UpPatent Expiration:Jan 27, 2029Product Flag?Substance Flag?Delist Request?Y

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
UBS
QuintilesIMS
Dow
Cerilliant
Queensland Health
Baxter
Julphar
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.